Quantum BioPharma Launches $7 Million Whistleblower Program Targeting Stock Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced the implementation of a public whistleblower policy offering cash rewards of up to USD $7 million for verifiable evidence of stock manipulation involving the Company's shares. The initiative, approved by the board and audit committee with input from multiple law firms, underscores Quantum's commitment to transparency, accountability, and market integrity while encouraging simultaneous reporting to the U.S. SEC and Canadian regulatory authorities. Eligible participants may submit information directly to the designated channels, with the reward payable from the net proceeds of the Company's ongoing lawsuit.

The reward will be granted if the submitted information materially contributes to a final, non-appealable judgment or binding settlement in Quantum BioPharma's favor. This substantial financial incentive represents one of the largest whistleblower programs in the biopharmaceutical sector specifically targeting stock manipulation. The company's approach reflects growing concerns about market manipulation affecting emerging biotech companies and demonstrates proactive measures to protect shareholder value. Quantum BioPharma maintains its focus on advancing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders while implementing these corporate governance enhancements.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also retains significant ownership in Unbuzzd Wellness Inc. and maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. Additional information about the specialized communications platform that distributed this announcement can be found at https://www.InvestorWire.com.

The whistleblower program represents a significant step in corporate accountability within the biopharmaceutical industry, where stock volatility can significantly impact research and development funding. By offering substantial financial incentives for credible information, Quantum BioPharma aims to deter potential market manipulation while strengthening investor confidence. The program's structure, requiring material contribution to legal outcomes, ensures that rewards are tied directly to successful enforcement actions. This initiative comes at a time when regulatory scrutiny of market manipulation practices is increasing across global financial markets, particularly affecting smaller publicly traded companies in high-growth sectors like biotechnology.